Generics Makers In India Have Eye On New U.S. Drug Policy
This article was originally published in PharmAsia News
Executive Summary
India's generic drug makers are watching closely for the new policies that will be put in place by the next U.S. president in the areas of drug regulation. They are concerned about whether the change of administrations from Republican to Democratic control will mean greater emphasis on generics, relaxation of current restrictions on government price-negotiations with drug makers and importation of U.S.-made drugs from other countries. Dr. Reddy's, Intas, Wockhardt and similar Indian companies also are interested in the new administration's take on the biologics that are their specialties. (Click here for more